Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Internet Draft Guidance: Firms Responsible For Promotions On Third-Party Sites

This article was originally published in The Pink Sheet Daily

Executive Summary

Social media draft guidance describes how and when interactive real-time promotional materials must be submitted for FDA review.

You may also be interested in...



Critics Call FDA Third-Party Social Media Guidance ‘Overbroad’

Some stakeholders are concerned the agency’s draft guidance is overreaching and could have a chilling effect. AdvaMed recommends FDA consider splitting the guidance into product-specific documents to reference regulations that may apply to industries differently.

Warning For Facebook “Likes” Reflects FDA Social Media Approach

FDA is revealing its views on social media use through individual enforcement actions and provisions in disparate guidances, in the absence of issuing an overarching guidance. A recent warning letter sheds light on the agency’s view of “liking” something on Facebook.

Off-Label Use Discussions Should Stay Off-line, FDA Draft Guidance Says

FDA advises companies to respond to unsolicited requests for off-label information in one-on-one dialogue; the agency also requests public comments on its policies regarding off-label communications in response to an industry citizen petition.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076365

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel